Biomarker-Driven Lung Cancer | Clinical

Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC

April 13, 2021

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

FDA Grants Sotorasib a Priority Review for KRAS G12C+ Advanced NSCLC

February 17, 2021

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.

Trastuzumab Deruxtecan Leads to Durable Responses in HER2-Mutant NSCLC

February 04, 2021

Trastuzumab deruxtecan induced a high objective response rate and durable responses among patients with HER2-mutant non–small cell lung cancer in a cohort of the phase 2 DESTINY Lung-01 trial, according to interim findings presented during the 2020 World Conference on Lung Cancer Singapore.

Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer Therapies

February 03, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

Larotrectinib Shows Activity in Lung Cancer Harboring NTRK Gene Fusions

February 02, 2021

Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

Repotrectinib Demonstrates Early Clinical Activity in ROS1+ Metastatic NSCLC

January 31, 2021

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.